Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 30;5(3):oeaf048.
doi: 10.1093/ehjopen/oeaf048. eCollection 2025 May.

Combined association of lipoprotein(a) and European Society of Cardiology Systematic COronary Risk Evaluation 2 (SCORE2) with 10-year major adverse cardiovascular events: evidence from a single tertiary hospital including 9979 patients

Kyuwoong Kim  1   2 , Minkyoung Kim  3 , Jiye Han  3 , Tae Joon Jun  4 , Young-Hak Kim  5
Affiliations

Combined association of lipoprotein(a) and European Society of Cardiology Systematic COronary Risk Evaluation 2 (SCORE2) with 10-year major adverse cardiovascular events: evidence from a single tertiary hospital including 9979 patients

Kyuwoong Kim et al. Eur Heart J Open. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
(A) Distribution of European Society of Cardiology Systematic COronary Risk Evaluation 2 by quintiles of lipoprotein(a) level in atherosclerotic patients. Note: Median and interquartile range for each lipoprotein(a) quintile are as follows (unit: mg/dL): Q1: 5.8 (4.6–6.9), Q2: 11.3 (9.7–13.0), Q3: 19.3 (17.0–21.9), Q4: 32.2 (28.2–37.2), and Q5: 65.8 (52.7–85.5). To convert the values for lipoprotein(a) to millimoles per litre, multiply by 2.5. (B) Distribution of major adverse cardiovascular events according to European Society of Cardiology Systematic COronary Risk Evaluation 2 and quintiles of liporpotein(a) level in atherosclerotic patients. (C) Cumulative incidence of major adverse cardiovascular events among atherosclerotic patients categorized by lipoprotein(a) level (Q1–4 and Q5) and European Society of Cardiology Systematic COronary Risk Evaluation 2 during 10 years of follow-up. (D) Combined association of lipoprotein(a) level and European Society of Cardiology Systematic COronary Risk Evaluation 2 with major adverse cardiovascular in atherosclerotic patients. Note: Hazard ratio and 95% confidence intervals presented above were calculated from Cox proportional hazards model adjusted for body mass index, atrial fibrillation, chronic kidney disease, subtypes of atherosclerotic cardiovascular disease (myocardial infarction, angina, asymptomatic coronary artery disease, ischaemic stroke/transient ischaemic attack, and peripheral artery disease), screening year for Lp(a), statin, and other lipid-lowering drugs. To convert the values for lipoprotein(a) to millimoles per litre, multiply by 2.5. European Society of Cardiology Systematic COronary Risk Evaluation 2 was calculated from the European Society of Cardiology Systematic COronary Risk Evaluation 2 chart for moderate region based on cardiovascular disease mortality (100 to <150 deaths from cardiovascular disease per 100 000 population). CI, confidence interval; ESC, European Society of Cardiology, Lp(a), lipoprotein(a); MACE, major adverse cardiovascular events; SCORE, Systematic COronary Risk Evaluation; No, number.
See this image and copyright information in PMC

References

    1. SCORE2 Working Group and ESC Cardiovascular Risk Collaboration . SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439–2454. - PMC - PubMed
    1. Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group . European guidelines on CVD prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on CVD prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–2381. - PMC - PubMed
    1. Eckardstein AV. Lipoprotein (a). Eur Heart J 2017;38:1530–1532. - PubMed
    1. Gencer B, Mach F. Lipoprotein (a): the perpetual supporting actor. Eur Heart J 2018;39:2597–2599. - PMC - PubMed
    1. Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein (a) and high risk of mortality. Eur Heart J 2019;40:2760–2770. - PubMed